280 related articles for article (PubMed ID: 19857798)
21. The Threshold of Toxicological Concern (TTC) in risk assessment.
Munro IC; Renwick AG; Danielewska-Nikiel B
Toxicol Lett; 2008 Aug; 180(2):151-6. PubMed ID: 18573621
[TBL] [Abstract][Full Text] [Related]
22. A probabilistic framework for non-cancer risk assessment.
Chen JJ; Moon H; Kodell RL
Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
[TBL] [Abstract][Full Text] [Related]
23. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
24. Refining the threshold of toxicological concern (TTC) for risk prioritization of trace chemicals in food.
Felter S; Lane RW; Latulippe ME; Llewellyn GC; Olin SS; Scimeca JA; Trautman TD
Food Chem Toxicol; 2009 Sep; 47(9):2236-45. PubMed ID: 19531369
[TBL] [Abstract][Full Text] [Related]
25. The Viracept-EMS case: impact and outlook.
Walker VE; Casciano DA; Tweats DJ
Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
[TBL] [Abstract][Full Text] [Related]
26. Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
Bercu JP; Galloway SM; Parris P; Teasdale A; Masuda-Herrera M; Dobo K; Heard P; Kenyon M; Nicolette J; Vock E; Ku W; Harvey J; White A; Glowienke S; Martin EA; Custer L; Jolly RA; Thybaud V
Regul Toxicol Pharmacol; 2018 Apr; 94():172-182. PubMed ID: 29408293
[TBL] [Abstract][Full Text] [Related]
27. Reichardt's dye and its reactions with the alkylating agents 4-chloro-1-butanol, ethyl methanesulfonate, 1-bromobutane and Fast Red B - a potentially useful reagent for the detection of genotoxic impurities in pharmaceuticals.
Corrigan DK; Whitcombe MJ; McCrossen S; Piletsky S
J Pharm Pharmacol; 2009 Apr; 61(4):533-7. PubMed ID: 19298702
[TBL] [Abstract][Full Text] [Related]
28. A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.
Hayes EP; Jolly RA; Faria EC; Barle EL; Bercu JP; Molnar LR; Naumann BD; Olson MJ; Pecquet AM; Sandhu R; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S39-47. PubMed ID: 27267172
[TBL] [Abstract][Full Text] [Related]
29. Permitted Daily Exposure for Diisopropyl Ether as a Residual Solvent in Pharmaceuticals.
Romanelli L; Evandri MG
Toxicol Res; 2018 Apr; 34(2):111-125. PubMed ID: 29686773
[TBL] [Abstract][Full Text] [Related]
30. An analysis of the risk of exceeding the acceptable or tolerable daily intake.
Renwick AG; Walker R
Regul Toxicol Pharmacol; 1993 Dec; 18(3):463-80. PubMed ID: 8128007
[TBL] [Abstract][Full Text] [Related]
31. Final report on the safety assessment of HC Red No. 7.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2008; 27 Suppl 1():45-54. PubMed ID: 18569161
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens.
Doak SH; Jenkins GJ; Johnson GE; Quick E; Parry EM; Parry JM
Cancer Res; 2007 Apr; 67(8):3904-11. PubMed ID: 17440105
[TBL] [Abstract][Full Text] [Related]
33. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
[TBL] [Abstract][Full Text] [Related]
34. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
35. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
Gerber C; Toelle HG
Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
[TBL] [Abstract][Full Text] [Related]
36. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal.
O'Brien J; Renwick AG; Constable A; Dybing E; Müller DJ; Schlatter J; Slob W; Tueting W; van Benthem J; Williams GM; Wolfreys A
Food Chem Toxicol; 2006 Oct; 44(10):1613-35. PubMed ID: 16887251
[TBL] [Abstract][Full Text] [Related]
37. Structure-based thresholds of toxicological concern--guidance for application to substances present at low levels in the diet.
Renwick AG
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):585-91. PubMed ID: 16019047
[TBL] [Abstract][Full Text] [Related]
38. No-observed effect levels are associated with up-regulation of MGMT following MMS exposure.
Doak SH; Brüsehafer K; Dudley E; Quick E; Johnson G; Newton RP; Jenkins GJ
Mutat Res; 2008 Dec; 648(1-2):9-14. PubMed ID: 18992265
[TBL] [Abstract][Full Text] [Related]
39. Pesticide residue analysis and its relationship to hazard characterisation (ADI/ARfD) and intake estimations (NEDI/NESTI).
Renwick AG
Pest Manag Sci; 2002 Oct; 58(10):1073-82. PubMed ID: 12400449
[TBL] [Abstract][Full Text] [Related]
40. In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances.
Bercu JP; Morton SM; Deahl JT; Gombar VK; Callis CM; van Lier RB
Regul Toxicol Pharmacol; 2010; 57(2-3):300-6. PubMed ID: 20363275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
